Aspartyiglycosaminuria (AGU) is a recessively inherited lysosomal storage disease that occurs with much higher frequency in Finlandthan elsewhere. AGU is caused by a deficiency in glycosylasparaginase (GA), which results in the accumulation of glycoasparagines in lysosomes. In the Finnish population, a single nucleotide change in the gene encoding GA is responsible for the disease. We have used the oligonucleotide ligation assay (OLA) to detect the mutation in polymerase chain reaction (PCR)-amplified DNA samples from normal, carrier, and affected individuals. Screening for AGU among 415 random Finn-ish DNA samples with PCR/OLA revealed five carriers of the mutant allele and demonstrated the potential of the method for use in carrier screen...
Mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo A disease) is a storage disorder caused by d...
BACKGROUND: Mucopolysaccharidosis type VI (MPS VI; Maroteaux -Lamy syndrome) is an autosomal recessi...
To investigate the feasibility of newborn screening for glycogen storage disease type II (GSDII; Pom...
AbstractAspartylglucosaminuria (AGU, McKusick 208400) is an autosomal recessive lysosomal storage di...
Aspartylglycosaminuria is an inherited lysosomal storage disease caused by deficiency of glycoaspara...
Aspartylglucosaminuria (AGU), a recessively inherited lysosomal storage disease, is the most common ...
SummaryAspartylglucosaminuria (AGU) is a lysosomal storage disease caused by a metabolic disorder of...
A new method is described for detection of mutations in the lysosomal a-glucosidase gene (GAA) leadi...
Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive lysosomal storage disorder caused by a...
Serum, plasma, and lymphocytes from aspartyiglycosami-nuria (AGU) patients and carriers and from nor...
Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder caused by the deficiency of N-ac...
Background The diagnostic workup in patients with a clinical suspicion of lysosomal storage diseases...
The functional activity of lysosomal enzymes sialidase, beta-galactosidase and N-acetylaminogalacto-...
Patients with glycogen storage disease type II (GSDII, Pompe disease) suffer from progressive muscle...
<p>Starting with pathogenic (DM) variants in HGMD (orange), incidence was estimated using allele fre...
Mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo A disease) is a storage disorder caused by d...
BACKGROUND: Mucopolysaccharidosis type VI (MPS VI; Maroteaux -Lamy syndrome) is an autosomal recessi...
To investigate the feasibility of newborn screening for glycogen storage disease type II (GSDII; Pom...
AbstractAspartylglucosaminuria (AGU, McKusick 208400) is an autosomal recessive lysosomal storage di...
Aspartylglycosaminuria is an inherited lysosomal storage disease caused by deficiency of glycoaspara...
Aspartylglucosaminuria (AGU), a recessively inherited lysosomal storage disease, is the most common ...
SummaryAspartylglucosaminuria (AGU) is a lysosomal storage disease caused by a metabolic disorder of...
A new method is described for detection of mutations in the lysosomal a-glucosidase gene (GAA) leadi...
Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive lysosomal storage disorder caused by a...
Serum, plasma, and lymphocytes from aspartyiglycosami-nuria (AGU) patients and carriers and from nor...
Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder caused by the deficiency of N-ac...
Background The diagnostic workup in patients with a clinical suspicion of lysosomal storage diseases...
The functional activity of lysosomal enzymes sialidase, beta-galactosidase and N-acetylaminogalacto-...
Patients with glycogen storage disease type II (GSDII, Pompe disease) suffer from progressive muscle...
<p>Starting with pathogenic (DM) variants in HGMD (orange), incidence was estimated using allele fre...
Mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo A disease) is a storage disorder caused by d...
BACKGROUND: Mucopolysaccharidosis type VI (MPS VI; Maroteaux -Lamy syndrome) is an autosomal recessi...
To investigate the feasibility of newborn screening for glycogen storage disease type II (GSDII; Pom...